Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alphamab OncologyALMOF 12 FCF Margin % is -52.55% as of Dec. 2025. GuruFocus rates ALMOF with a GF Score™ of 12/100 and a GF Value™ of $0.87 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 956 Biotechnology companies, Alphamab Oncology ranks better than 61.09% on this metric.
The historical data trend for Alphamab Oncology's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALMOF vs VRTX, REGN, RVMD: FCF Margin % Comparison
For the Biotechnology subindustry, Alphamab Oncology's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alphamab Oncology FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alphamab Oncology's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Alphamab Oncology's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alphamab Oncology (ALMOF) has a FCF Margin % of -52.55% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Alphamab Oncology and its competitors. According to the industry distribution chart, Alphamab Oncology ranks #372 out of 956 companies in the Biotechnology industry, placing it in the top 38.9%.
Is Alphamab Oncology's FCF Margin % too high?
Alphamab Oncology's current FCF Margin % is -52.55%. Based on the distribution chart, Alphamab Oncology ranks #372 out of 956 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Alphamab Oncology has a GF Score™ of 12/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alphamab Oncology's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alphamab Oncology ranks #372 out of 956 companies for FCF Margin %. This puts Alphamab Oncology in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Alphamab Oncology and its competitors. Alphamab Oncology's current FCF Margin % is -52.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alphamab Oncology stock overvalued right now?
Based on GuruFocus' analysis, Alphamab Oncology (ALMOF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.87, compared to a current price of $1.02 — trading 17.4% above its estimated fair value. The current FCF Margin % is -52.55%. Alphamab Oncology's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Alphamab Oncology (ALMOF), the current FCF Margin % is -52.55% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alphamab Oncology (ALMOF) Overvalued in 2026?
Based on GuruFocus' analysis, Alphamab Oncology stock appears to be overvalued.
The current stock price of $1.02 is trading 17.4% above its estimated GF Value™ of $0.87.
GuruFocus considers Alphamab Oncology to be Modestly Overvalued.
Key valuation signals for ALMOF:
FCF Margin %: -52.55%
GF Value™: $0.87 vs. price of $1.02 (17.4% above fair value)
No single metric tells the full story. See the ALMOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
12GF Score
Get the complete analysis for ALMOF
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALMOF has been successfully added to your 
